157 related articles for article (PubMed ID: 2154420)
1. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
2. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
[TBL] [Abstract][Full Text] [Related]
3. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
Coleman CN; Buswell L; Noll L; Riese N; Rose MA
Int J Radiat Oncol Biol Phys; 1992; 22(3):565-8. PubMed ID: 1310497
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
8. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen NM; Newman HF; Maughan TS; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
[TBL] [Abstract][Full Text] [Related]
9. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
10. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Coleman CN; Noll L; Howes AE; Harris JR; Zakar J; Kramer RA
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
[TBL] [Abstract][Full Text] [Related]
11. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
[TBL] [Abstract][Full Text] [Related]
12. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Bleehen NM; Maughan TS; Workman P; Newman HF; Stenning S; Ward R
Radiother Oncol; 1991; 20 Suppl 1():137-42. PubMed ID: 1826962
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).
Wasserman TH; Lee DJ; Cosmatos D; Coleman N; Phillips T; Davis L; Marcial V; Stetz J
Radiother Oncol; 1991; 20 Suppl 1():129-35. PubMed ID: 1826961
[TBL] [Abstract][Full Text] [Related]
15. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
16. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
Workman P; Ward R; Maughan TS; Newman HF; Bleehen NM
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):177-81. PubMed ID: 2526107
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic cell radiosensitizers: expectations and progress in drug development.
Coleman CN
Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
[TBL] [Abstract][Full Text] [Related]
18. Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.
Chassagne D; Sancho-Garnier H; Charreau I; Eschwege F; Malaise EP
Radiother Oncol; 1991; 20 Suppl 1():121-7. PubMed ID: 1826960
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]